Follow
Jeremie Guedj
Jeremie Guedj
Researcher at the French Institute of Health and Medical Research (INSERM)
Verified email at inserm.fr - Homepage
Title
Cited by
Cited by
Year
Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea
D Sissoko, C Laouenan, E Folkesson, AB M’lebing, AH Beavogui, S Baize, ...
PLoS medicine 13 (3), e1001967, 2016
5792016
Autoantibodies neutralizing type I IFNs are present in~ 4% of uninfected individuals over 70 years old and account for~ 20% of COVID-19 deaths
P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, J Manry, ...
Science immunology 6 (62), eabl4340, 2021
4552021
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life
J Guedj, H Dahari, L Rong, ND Sansone, RE Nettles, SJ Cotler, ...
Proceedings of the National Academy of Sciences 110 (10), 3991-3996, 2013
4152013
Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates
P Maisonnasse, J Guedj, V Contreras, S Behillil, C Solas, R Marlin, ...
Nature 585 (7826), 584-587, 2020
3862020
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled …
F Ader, M Bouscambert-Duchamp, M Hites, N Peiffer-Smadja, J Poissy, ...
The Lancet infectious diseases 22 (2), 209-221, 2022
3572022
X-linked recessive TLR7 deficiency in~ 1% of men under 60 years old with life-threatening COVID-19
T Asano, B Boisson, F Onodi, D Matuozzo, M Moncada-Velez, ...
Science immunology 6 (62), eabl4348, 2021
3412021
Timing of antiviral treatment initiation is critical to reduce SARS‐CoV‐2 viral load
A Gonçalves, J Bertrand, R Ke, E Comets, X De Lamballerie, D Malvy, ...
CPT: pharmacometrics & systems pharmacology 9 (9), 509-514, 2020
2182020
Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort
N Néant, G Lingas, Q Le Hingrat, J Ghosn, I Engelmann, Q Lepiller, ...
Proceedings of the National Academy of Sciences 118 (8), e2017962118, 2021
2052021
Ebola virus infection: review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials
V Madelain, THT Nguyen, A Olivo, X De Lamballerie, J Guedj, AM Taburet, ...
Clinical pharmacokinetics 55 (8), 907-923, 2016
2052016
Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate
RM Ribeiro, H Li, S Wang, MB Stoddard, GH Learn, BT Korber, ...
Public Library of Science 8 (8), e1002881, 2012
1912012
Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted
THT Nguyen, J Guedj, X Anglaret, C Laouénan, V Madelain, AM Taburet, ...
PLoS neglected tropical diseases 11 (2), e0005389, 2017
1792017
Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model
JS Driouich, M Cochin, G Lingas, G Moureau, F Touret, PR Petit, ...
Nature communications 12 (1), 1735, 2021
1402021
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies
J Manry, P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, ...
Proceedings of the National Academy of Sciences 119 (21), 2022
1332022
Dose regimen of favipiravir for Ebola virus disease
F Mentré, AM Taburet, J Guedj, X Anglaret, S Keïta, X de Lamballerie, ...
The Lancet Infectious Diseases 15 (2), 150-151, 2015
1332015
Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques
J Guedj, G Piorkowski, F Jacquot, V Madelain, THT Nguyen, A Rodallec, ...
PLoS medicine 15 (3), e1002535, 2018
1322018
Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study
D Sissoko, S Duraffour, R Kerber, JS Kolie, AH Beavogui, AM Camara, ...
The Lancet Global Health 5 (1), e80-e88, 2017
1312017
Second‐phase hepatitis C virus RNA decline during telaprevir‐based therapy increases with drug effectiveness: implications for treatment duration
J Guedj, AS Perelson
Hepatology 53 (6), 1801-1808, 2011
1272011
Quantifying the relationship between SARS-CoV-2 viral load and infectiousness
A Marc, M Kerioui, F Blanquart, J Bertrand, O Mitja, M Corbacho-Monné, ...
Elife 10, e69302, 2021
1212021
Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model
L Rong, J Guedj, H Dahari, DJ Coffield Jr, M Levi, P Smith, AS Perelson
PLoS computational biology 9 (3), e1002959, 2013
1172013
Maximum likelihood estimation in dynamical models of HIV
J Guedj, R Thiébaut, D Commenges
Biometrics 63 (4), 1198-1206, 2007
1142007
The system can't perform the operation now. Try again later.
Articles 1–20